Celyad Oncology (XBRU:CYAD) Price-to-Operating-Cash-Flow : (As of May. 06, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Price-to-Operating-Cash-Flow?

As of today (2024-05-06), Celyad Oncology's share price is €0.308. Celyad Oncology's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2023 was €0.00. Hence, Celyad Oncology's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Celyad Oncology's Price-to-Operating-Cash-Flow or its related term are showing as below:

XBRU:CYAD's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 26.23
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Celyad Oncology's Cash Flow from Operations per share for the three months ended in Jun. 2023 was €0.00. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2023 was €0.00.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 18.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 19.90% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 3.20% per year.

During the past 12 years, Celyad Oncology's highest 3-Year average Operating Cash Flow per Share Growth Rate was 24.50% per year. The lowest was -34.70% per year. And the median was 7.00% per year.

Celyad Oncology Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Celyad Oncology's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Price-to-Operating-Cash-Flow Chart

Celyad Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Celyad Oncology's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Celyad Oncology's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Price-to-Operating-Cash-Flow falls into.

Celyad Oncology Price-to-Operating-Cash-Flow Calculation

Celyad Oncology's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.308	/	0
	=

Celyad Oncology's Share Price of today is €0.308.
Celyad Oncology's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Celyad Oncology Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (XBRU:CYAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

1C0:Germany

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (XBRU:CYAD) Headlines

No Headlines